Guggenheim Capital LLC Increases Position in Bristol-Myers Squibb (NYSE:BMY)

Guggenheim Capital LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 723,676 shares of the biopharmaceutical company’s stock after purchasing an additional 2,398 shares during the period. Guggenheim Capital LLC’s holdings in Bristol-Myers Squibb were worth $40,931,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Chiron Investment Management LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $4,768,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $19,663,000. Canada Post Corp Registered Pension Plan purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $4,593,000. Promethos Capital LLC boosted its holdings in shares of Bristol-Myers Squibb by 6,910.8% in the 4th quarter. Promethos Capital LLC now owns 83,709 shares of the biopharmaceutical company’s stock valued at $4,735,000 after buying an additional 82,515 shares in the last quarter. Finally, Mariner LLC grew its position in shares of Bristol-Myers Squibb by 2.2% in the 4th quarter. Mariner LLC now owns 887,028 shares of the biopharmaceutical company’s stock valued at $50,167,000 after buying an additional 19,292 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,823 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.2 %

Shares of NYSE:BMY opened at $51.33 on Tuesday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm’s 50-day simple moving average is $57.54 and its 200-day simple moving average is $56.78. The company has a market cap of $104.44 billion, a price-to-earnings ratio of -11.61, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.83%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Analysts Set New Price Targets

Several equities analysts have issued reports on BMY shares. UBS Group decreased their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday. Cantor Fitzgerald upped their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their target price for the company from $63.00 to $70.00 in a report on Monday, December 16th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $57.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.